Tirofiban Other names: Tirofiban hydrochloride

Chemical formula: C₂₂H₃₆N₂O₅S  Molecular mass: 440.597 g/mol  PubChem compound: 60947

Therapeutic indications

Tirofiban is indicated for:

Acute coronary syndromes without ST elevation (NSTE-ACS)

Population group: only adults (18 years old or older)

Tirofiban is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.

Patients most likely to benefit from Tirofiban treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). Tirofiban is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI.

Tirofiban is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tirofiban is contraindicated in the following cases:

Severe liver failure

Hepatic failure stage IV

Prothrombin time >1.3 times normal, INR [International Normalised Ratio] >1.5

at least one of
Prothrombin time increased
International normalized ratio above reference range

Thrombocytopenia

Thrombocytopenic disorder

Relevant trauma, major surgical intervention

at least one of
H/O: major vascular surgery
H/O: major abdominal surgery
History of major orthopedic surgery
History of cardiovascular surgery
Traumatic injury

Malignant hypertension

Malignant hypertension

Bleeding

Bleeding

Intracranial neoplasm, arteriovenous malformation, aneurysm

at least one of
Intracranial tumour
Cerebral aneurysm
Intracranial vascular malformation

Stroke, haemorrhagic stroke

at least one of
CVA - Cerebrovascular accident
Intracranial hemorrhage

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: TIROFIBAN Solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈